The QIAseq Targeted DNA Pro Focus Panels enable a Sample to Insight workflow for a targeted next generation sequencing analysis of actionable and interpretable cancer-related somatic variants in oncogenes and tumor suppressor genes relevant for tumor classification.

We specifically collect targeted actionable and interpretable genes and variants from

1. clinical practice guidelines recommended by multiple organizations, including the American College of Medical Genetics (ACMG), the American Society Of Hematology (ASH), the Association for Molecular Pathology (AMP), the American Society of Clinical Oncology (ASCO), the College of American Pathologists (CAP), the European Society for Medical Oncology (ESMO), and the National Comprehensive Cancer Network (NCCN);
2. the NIH NCBI ClinVar and Online Mendelian Inheritance in Man (OMIM) resources that compile variants with known associations to cancers cited by peer-reviewed publications,
3. clinical trial documents from resources such as Cancer.gov, ClinicalTrials.gov, and the UMIN Clinical Trials Registry;
4. requests and suggestions from QIAGEN KOLs and SMEs; and
5. other peer-reviewed publications.

Building on our expertise to employ unique molecular indices (UMIs) to correct for PCR amplification bias and to use single primer extension (QIAseq enrichment technology) technology for highly-specific target enrichment, QIAseq Targeted DNA Pro Panels offer a streamlined library preparation workflow that takes less than 6 hours with minimum hands-on time.

The simplicity of QIAseq Targeted DNA Pro Focus Panels is ideal for routine known cancer mutation detection and screening in any research laboratory with access to next-generation sequencing (NGS) platforms from Illumina and Ion Torrent.

The QIAseq Targeted DNA Pro Research Panels enable a Sample to Insight workflow for a targeted next generation sequencing analysis of the entire coding region of relevant oncogenes and tumor suppressor genes. The panels also target actionable and interpretable cancer-related somatic variants relevant for tumor classification.

We specifically collect targeted actionable and interpretable genes and variants from

1. clinical practice guidelines recommended by multiple organizations, including the American College of Medical Genetics (ACMG), the American Society Of Hematology (ASH), the Association for Molecular Pathology (AMP), the American Society of Clinical Oncology (ASCO), the College of American Pathologists (CAP), the European Society for Medical Oncology (ESMO), and the National Comprehensive Cancer Network (NCCN);
2. the NIH NCBI ClinVar and Online Mendelian Inheritance in Man (OMIM) resources that compile variants with known associations to cancers cited by peer-reviewed publications,
3. clinical trial documents from resources such as Cancer.gov, ClinicalTrials.gov, and the UMIN Clinical Trials Registry;
4. requests and suggestions from QIAGEN KOLs and SMEs; and
5. other peer-reviewed publications.

Building on our expertise to employ unique molecular indices (UMIs) to correct for PCR amplification bias and to use single primer extension (QIAseq enrichment technology) technology for highly-specific target enrichment, QIAseq Targeted DNA Pro Panels offer a streamlined library preparation workflow that takes less than 6 hours with minimum hands-on time.

The simplicity of QIAseq Targeted DNA Pro Research Panels is ideal for routine known and novel cancer mutation detection and screening in any research laboratory with access to next-generation sequencing (NGS) platforms from Illumina and Ion Torrent.

The QIAseq Targeted DNA Pro Hereditary Cancer Panels enable a Sample to Insight workflow for a targeted next generation sequencing analysis of the entire coding region of relevant oncogenes and tumor suppressor genes. The panels also target actionable and interpretable cancer-related germline variants relevant for tumor classification.

We specifically collect targeted actionable and interpretable genes and variants from

1. clinical practice guidelines recommended by multiple organizations, including the American College of Medical Genetics (ACMG);
2. the NIH NCBI ClinVar and Online Mendelian Inheritance in Man (OMIM) resources that compile variants with known associations to cancers cited by peer-reviewed publications,
3. the St. Jude Children's Research Hospital’s Pediatric Cancer Genome Project list of discovered driver mutations;
4. requests and suggestions from QIAGEN KOLs and SMEs; and
5. other peer-reviewed publications.

Building on our expertise to employ unique molecular indices (UMIs) to correct for PCR amplification bias and to use single primer extension (QIAseq enrichment technology) technology for highly-specific target enrichment, QIAseq Targeted DNA Pro Panels offer a streamlined library preparation workflow that takes less than 6 hours with minimum hands-on time.

The simplicity of QIAseq Targeted DNA Pro Hereditary Cancer Panels is ideal for routine known and novel cancer mutation detection and screening in any research laboratory with access to next-generation sequencing (NGS) platforms from Illumina and Ion Torrent.